Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) Cost of Revenue: 2019-2024

Historic Cost of Revenue for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to $111.1 million.

  • GeneDx Holdings' Cost of Revenue rose 10.92% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.1 million, marking a year-over-year increase of 12.74%. This contributed to the annual value of $111.1 million for FY2024, which is 1.34% down from last year.
  • As of FY2024, GeneDx Holdings' Cost of Revenue stood at $111.1 million, which was down 1.34% from $112.6 million recorded in FY2023.
  • GeneDx Holdings' 5-year Cost of Revenue high stood at $261.4 million for FY2022, and its period low was $111.1 million during FY2024.
  • Over the past 3 years, GeneDx Holdings' median Cost of Revenue value was $112.6 million (recorded in 2023), while the average stood at $161.7 million.
  • Per our database at Business Quant, GeneDx Holdings' Cost of Revenue surged by 54.60% in 2020 and then slumped by 56.95% in 2023.
  • Over the past 5 years, GeneDx Holdings' Cost of Revenue (Yearly) stood at $175.3 million in 2020, then surged by 30.52% to $228.8 million in 2021, then climbed by 14.27% to $261.4 million in 2022, then plummeted by 56.95% to $112.6 million in 2023, then declined by 1.34% to $111.1 million in 2024.